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Abstract
 
In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8
 
 
 
 cytotoxic
T lymphocyte (CTL) responses are associated with initial control of viremia. Despite these re-
sponses, 70–80% of individuals develop persistent infection. Although viral escape from CD8
responses has been illustrated in the chimpanzee model of HCV infection, the effect of CD8
selection pressure on viral evolution and containment in acute HCV infection in humans re-
mains unclear. Here, we examined viral evolution in an immunodominant human histocom-
patibility leukocyte antigen (HLA)-B8–restricted NS3 epitope in subjects with acute HCV in-
fection. Development of mutations within the epitope coincided with loss of strong ex vivo
tetramer and interferon 
 
 
 
 enzyme-linked immunospot responses, and endogenous expression
of variant NS3 sequences suggested that the selected mutations altered processing and presentation
of the variant epitope. Analysis of NS3 sequences from 30 additional chronic HCV-infected
subjects revealed a strong association between sequence variation within this region and ex-
pression of HLA-B8, supporting reproducible allele-specific selection pressures at the popula-
tion level. Interestingly, transmission of an HLA-B8–associated escape mutation to an HLA-B8
negative subject resulted in rapid reversion of the mutation. Together, these data indicate that
viral escape from CD8
 
 
 
 T cell responses occurs during human HCV infection and that acute
immune selection pressure is of sufficient magnitude to influence HCV evolution.
Key words: HLA footprint • processing mutation • viral evolution • acute hepatitis C • 
CD8 escape
 
Introduction
 
Hepatitis C is a common cause of liver disease (1) with the
majority of infected individuals developing persistent high-
level viremia, some of whom go on to develop progressive
hepatic fibrosis. Clearance of the virus during acute infec-
tion has been shown to be associated with a strong and
broadly directed cellular immune response mediated by
both CD4
 
 
 
 and CD8
 
 
 
 T cells (2–6) and the importance of
these cell subtypes in the control of viral infection has been
demonstrated in the chimpanzee model through T cell de-
pletion studies (7, 8). However, although many individuals
mount detectable cellular immune responses in the acute
phase of infection (4, 6), the majority of these subjects still
progress to chronic disease. Complicating our ability to de-
termine the role of the immune response in control of hep-
atitis C virus (HCV) is that once viral persistence is established,
CD4
 
 
 
 and CD8
 
 
 
 T cell responses become difficult to detect
(9–11). When present in blood, they are typically very
weak, but can often be detected after peptide-specific re-
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stimulation in vitro or by using ultra-sensitive tetramer
staining techniques (12). The frequency of these cells may
be enriched in the liver (13, 14), although even here many
patients appear to lack responses (15).
The mechanisms of viral persistence in the face of an acti-
vated host immune response in addition to the differences
between cellular immune responses in individuals who suc-
cessfully control the virus versus those who fail to control are
poorly understood. Several mechanisms suspected to con-
tribute to failure to contain HCV have been suggested (16),
including impairment of cellular effector functions (prolifer-
ation, cytokine secretion, and cytolytic activity; references 6,
17, 18), dendritic cell dysfunction (19), or T cell exhaustion
(20). In addition, the liver as the main site of HCV infection,
and therefore antigen presentation, has the potential to de-
lete antigen-specific T cell responses (21).
Persistence of HCV may also be facilitated by viral evo-
lution over the course of infection, enabling escape from
prominent CD8
 
 
 
 CTL responses. The emergence of CD8
escape variants has been demonstrated in numerous viral
infections (HIV, SIV, LCMV, influenza), although the im-
pact of immune escape on disease progression remains less
well understood (22–26). In HCV infection, a strong asso-
ciation between viral persistence and the development of
escape mutations has been demonstrated in the chimpanzee
model (27). However, in human HCV infection, the find-
ings are less clear. Thus far, most CD8 escape studies have
been limited in their analysis by the lack of longitudinal
samples from patients with acute infection (28). A correla-
tion between the outcome of acute hepatitis C and the
evolution of quasispecies has been described and the selec-
tion of site-specific mutations in the envelope gene E2 ob-
served (29, 30), but this has not been linked to specific
CD4 or CD8 T cell responses. In longitudinal studies in
which selected CD8 responses restricted by common HLA
class I molecules were studied, no evolution was found
within most targeted epitopes (31), and in some of these
cases, exhaustion as a mechanism for T cell failure has been
favored (20).
To more precisely address the role of viral escape on
CD8 T cell recognition, we examined the relationship be-
tween a targeted immunodominant HLA-B8–restricted
epitope and in vivo viral evolution in two HLA-B8 posi-
tive subjects with acute infection. Viral sequences in this
epitope were also examined in a larger cohort of chronic
HCV-infected subjects to assess whether HLA-associated
mutations could also be detected at the population level.
These data illustrate consistent allele-specific viral evolution
and escape from a dominant CD8 response in human HCV
infection. Moreover, transmission of a CD8 escape muta-
tion in the absence of ongoing selecting immune pressure
enabled reversion of the mutation to the original sequence.
Together, these data indicate that cellular immune pres-
sures can be exerted during acute HCV infection and can
reproducibly influence HCV evolution.
 
Materials and Methods
 
Subjects.
 
Subject 99B developed acute hepatitis C after a nee-
dle stick injury (Table I and see Fig. 2 A). 5 wk after the injec-
tion, the subject continued to have HCV RNA levels 
 
 
 
2.0 
 
 
 
10
 
6
 
 IU/ml (HCV Roche Amplicor assay, detection limit 
 
 
 
600
IU/ml), and therapy was initiated with interferon 
 
 
 
-2b. During
the ensuing 12 mo of treatment, HCV RNA levels were at or
below the level of detection in quantitative assays. After cessation
of therapy, viral loads relapsed to a level of 0.5 
 
 
 
 10
 
6
 
 IU/ml.
Subject 02J (donor) was identified after donating blood to a re-
cipient (subject 02K, see next paragraph) who developed acute
HCV infection (Table I and see Fig. 1). 02J was seronegative at
the time of the blood donation but subsequently seroconverted
between 7 and 9 wk later (EIA 3.0; Abbott Diagnostics), consis-
tent with infection shortly before the transfusion event. Before
treatment, 02J exhibited 0.3–0.5 
 
 
 
 10
 
6
 
 U/ml viral loads (see Fig.
2 A). Treatment with peginterferon 
 
 
 
-2b and ribavirin was
started 15 wk after the transfusion, and the HCV RNA level de-
clined to below the level of detection (
 
 
 
600 IU/ml). However,
27 wk after initiating therapy, the HCV RNA became consis-
tently detectable at pretreatment levels, and therapy was stopped.
Subject 02K received a transfusion from 02J (Table I and see
Fig. 1) and, 35 d later, HCV plasma RNA was 0.8–1.0 
 
 
 
 10
 
6
 
IU/ml (see Fig. 2 A). At the time of presentation, subject 02K
was asymptomatic. Treatment with peginterferon 
 
 
 
-2b and ri-
bavirin was started 13 wk after transfusion and a virological re-
sponse with undetectable plasma HCV RNA was achieved.
However, the subject had virologic relapse when medication was
stopped after 24 wk of treatment. Thereafter, HCV RNA tran-
siently declined between weeks 52 and 64 before again rebound-
ing to pretreatment levels. The immune responses and viral loads
over the course of infection of these three subjects have been
studied in the context of a larger cohort of acute HCV infection
(unpublished data), and are repeated here for clarity.
 
Table I.
 
Study Subjects and Targeted CD8 Epitopes
 
Subjects Route of infection GT HLA
Epitopes/HLA
restriction Protein H77 reference sequence
99B needle stick 1b A3, 11 B7, 8 Cw7 1395-1403/B8
1636-1644
NS3
NS4
HSKKKCDEL
EVTLTHPITKYIMTCMSA
02J unknown (donor for 02K) 1a A1, B8, 44 Cw5, 7 1395-1403/B8 NS3 HSKKKCDEL
02K transfusion (recipient of 02J) 1a A31, 68 B40, 44 Cw3, 7 – – NA
NA, not applicable. 
Timm et al.
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In addition, 30 treatment-naive subjects with chronic HCV
infection were recruited from the Hepatology Outpatient Clinic
of the Massachusetts General Hospital in Boston. Subjects were
included if they presented with positive HCV RNA in the serum
(range: 0.05–15 
 
 
 
 10
 
6
 
 U/ml) and no anamnestic evidence of
acute hepatitis within the previous 6 mo. Fibrosis was present in
20/23 subjects in liver biopsy. The range of ALT was 22–214
U/ml. All subjects were infected with genotype 1a or 1b (see Ta-
ble III). The study was approved by the local Institutional Re-
view Board and all subjects gave written informed consent.
 
IFN-
 
 
 
 ELISPOT Assay.
 
HCV-specific CD8
 
 
 
 T cell responses
were quantified by ELISPOT assay as described previously (10)
using 301 overlapping peptides (20-mer peptides overlapping by
10 amino acids) spanning the entire expressed HCV-H77 genome
(genotype 1a), as well as 83 peptides corresponding to optimal
described CTL epitopes (32) and autologous virus sequences as
indicated. Comparison of autologous and variant epitopes was
performed using log
 
10
 
 dilutions of peptides as described previ-
ously (10). For quantitation of ex vivo responses, the assay was
performed at least in duplicate and background was not 
 
 
 
15
spot-forming cells/10
 
6
 
 PBMCs. Responses were considered posi-
tive if the number of spots per well minus the background was at
least 25 SFC/10
 
6
 
 PBMCs (33). PHA served as a positive control
for T cell stimulation.
 
51
 
Cr Release Assay.
 
Cytotoxicity assays were performed as
described previously (10). Autologous EBV-transformed B cells
were incubated in Na
 
2
 
[
 
51
 
Cr]O
 
4
 
 (New England Nuclear) for 1 h
at 37
 
 
 
C in 5% CO
 
2
 
. The cells were washed three times with cold
R10 media (RPMI 1640, 10% FCS, and 10 mM Hepes buffer [all
obtained from Sigma-Aldrich] with 2 mM glutamine and antibi-
otics [50 U/ml penicillin-streptomycin]) and incubated with
log
 
10
 
 dilutions of peptides and effector cells at 37
 
 
 
C for 4 h at an
E:T ratio of 30:1. Cellular release of 
 
51
 
Cr into the supernatant
was measured using a Top Count Microplate scintillation counter
(Packard Instrument Co.), and the percent specific cytotoxicity
was calculated by the formula % lysis 
 
 
 
 [(experimental release 
 
 
 
spontaneous release)/(maximum release 
 
 
 
 spontaneous release)] 
 
 
 
100. Results are reported as the mean of triplicate values, with a
standard deviation of 
 
 
 
5%.
 
Intracellular Cytokine Staining (ICS).
 
ICS for IFN-
 
 
 
 was per-
formed as described previously (10). In brief, 10
 
6
 
 PBMCs were in-
cubated with 4 
 
 
 
g/ml peptide at 37
 
 
 
C and 5% CO
 
2
 
 for 1 h before
the addition of Brefeldin A (1 
 
 
 
l/ml; Sigma-Aldrich). The cells
were incubated for an additional 5 h at 37
 
 
 
C and 5% CO
 
2
 
. PB-
MCs were washed and stained with surface antibodies, allophyco-
cyanin-conjugated anti-CD8, and PE-conjugated anti-CD3 (Bec-
ton Dickinson) at 4
 
 
 
C for 20 min. After the washing, the PBMCs
were fixed and permeabilized (Caltag), and the FITC-conjugated
anti–IFN-
 
 
 
 mAb (Becton Dickinson) was added. Cells were
washed and analyzed on a FACS-Calibur flow cytometer using
CELLQuest software (Becton Dickinson). Data analysis was per-
formed with the FlowJo software package (TreeStar).
 
HLA Class I–Peptide Tetramer Staining.
 
An HLA class I–pep-
tide tetramer specific for the targeted B8-1395 epitope (HS-
KKKCDEL) was synthesized as described previously (34). Tet-
ramer staining was performed for 20 min at 37
 
 
 
C using 0.5–10
 
6
 
PBMCs as described previously (4). After washing for 5 min with
PBS containing 1% FCS at room temperature (RT), cells were
pelleted and directly stained with CD8-PerCP (from Becton
Dickinson). All staining was performed in PBS in the presence of
10% goat immunoglobulin. Background staining was 0.05% of
the CD8
 
 
 
 T cell population in an HLA-unmatched control.
Staining was considered positive in 99B if tetramer positive cells
formed a cluster distinct from the tetramer negative CD8
 
 
 
 T cell
population and the frequency of tetramer positive cells was
 
 
 
0.1%. Backround was higher for 02J; therefore only stainings
 
 
 
0.4% of the CD8
 
 
 
 T cell population were considered positive
in this subject.
 
Bulk Stimulation of PBMCs.
 
To establish CD8
 
 
 
 T cell lines,
cryopreserved or fresh PBMCs (4–10 
 
 
 
 10
 
6
 
) were stimulated
with 1 
 
 
 
g/ml of synthetic HCV peptide and 0.5 
 
 
 
g/ml of the
costimulatory antibodies anti-CD28 and anti-CD49d (Becton
Dickinson) in R10 media. Recombinant IL-2 (25 IU/ml) was
added on day 2 and twice a week thereafter. Cells were restimu-
lated with 25 
 
 
 
 10
 
6
 
 irradiated PBMCs after 2 wk.
 
Sequencing of Autologous Virus.
 
Viral RNA was extracted from
plasma samples using the vRNA extraction kit (QIAGEN). Where
necessary, samples were pretreated with 1 U/
 
 
 
l heparinase I
(Sigma-Aldrich) before RNA isolation. Specific primers were de-
signed for genotypes 1a and 1b based on alignments of all available
sequences from the public HCV Database (http://hcvpub.ibcp.fr).
In a combined reverse transcription and first round PCR step, a
1,288-bp fragment for genotype 1a (primers 4a-F, 5
 
 
 
-AGTGC-
CCCAGAGCTTCCAGG-3
 
 
 
 and 4d-R, 5
 
 
 
-ACCCAGGTGC-
TCGTGACG-3
 
 
 
) and a 1,361-bp fragment for genotype 1b
(primers 4a-F, 5
 
 
 
-ATGGAAACTACYATGCGG-3
 
 
 
 and 4d-R,
5
 
 
 
-CCAGGTGCTVGTGACGACC) were amplified. Nested prim-
ers amplifying overlapping internal fragments were used in a sec-
ond round PCR as follows: for genotype 1a, 4b-F, 5
 
 
 
-GTAA-
GAGCACCAAGGTCCC-3
 
 
 
; 4b–R, 5
 
 
 
-GCAGTCTATCAC-
CGAGTCG-3
 
 
 
; 4c-F 5
 
 
 
-CGAGGAGGTTGCTCTGTCC-3
 
 
 
;
and 4c–R 5
 
 
 
-AGCACAGCCYGCGTCATAGC-3
 
 
 
; for geno-
type 1b, 4b-F, 5
 
 
 
-AAGGACCATCACCACGGG-3
 
 
 
; 4b–R 5
 
 
 
-
CATTAGAGCGTCTGTTGC-3
 
 
 
; 4c-F, 5
 
 
 
-CTATGGCAAA-
GCCATCCC-3
 
 
 
; and 4c–R, 5
 
 -GGTGTATTTAGGTAAGC-
CCG-3 . Using the QIAGEN One-Step RT-PCR kit, RT-PCR
cycling conditions were as follows: 50 C for 60 min and 95 C for
15 min, followed by 35 cycles of 30 s at 94 C, 30 s at 54 C, 1.5
min at 72 C, and a final extension of 68 C for 20 min. Nested
PCR conditions were 35 cycles of 30 s at 94 C, 30 s at 62 C, 1
min at 72 C, and a final extension of 68 C for 20 min using a
high fidelity Taq DNA polymerase (titanium Taq DNA poly-
merase; CLONTECH Laboratories, Inc.). PCR fragments were
gel or PCR purified (QIAGEN kit) and the population was
sequenced bidirectionally on an ABI 3100 PRISM automated
sequencer. When necessary, PCR products were also cloned
(TOPO TA; Invitrogen) and sequenced. To avoid quasispecies
selection due to primer specificities, clonal data from two differ-
ent primer pairs were generated resulting in similar clonal fre-
quencies. Sequencher (Gene Codes Corp.) and MacVector 4.1
(Oxford Molecular) software programs were used to edit and
align sequences. These sequence data are available from GenBank
under accession nos. AY707283-312 and AY712793-937.
mRNA Transfection of B Cells. An 837-bp fragment contain-
ing the epitope region was amplified from subject 02J in weeks
7, 15, and 57 (using primers 4b-F and 4c-R) and cloned. These
clones served as template for a second round PCR using a
forward primer containing a T7 promoter sequence (5 –
TAATACGACTCACTATAGGGAGAGCCACCATGGATG-
AGTGCCACTCCACG-3 ) and a reverse primer containing an
additional sequence coding for the described HLA-B8–restricted
HIV epitope FL8 (FLKEKGGL) followed by a stop codon (5 -
TCACAGTCCCCCCTTTTCTTTTAAAAATTGAGTGCG-
GCAGACAGC-3 ). The constructs (479 bp) were confirmed
to yield the correct sequence and served as a template to gener-
ate mRNA (mMessage T7 machine; Ambion) with a poly (A)CTL Escape in Acute HCV Infection 1596
tail added (poly (A) tailing kit; Ambion). 106 HLA-B8–positive,
EBV-transformed, immortalized B cells were washed twice with
Optimum media and incubated with 20  g mRNA or mock for
10 min on ice. Cells were electroporated (300 mV, 0.5 ms;
GenePulse; Bio-Rad Laboratories) and directly transferred to a
plate containing R10. After 16 h, cells were washed once in R10
and cocultured with effector cells at a 5:1 E:T ratio for 1 h.
HLA Typing. HLA typing was performed by the Tissue
Typing Laboratory at the Churchill Hospital in Oxford, and the
Massachusetts General Hospital Tissue Typing Laboratory using
standard serological and molecular techniques (35).
Phylogenetic and Selection Analysis. Maximum likelihood (ML)
phylogenetic trees were estimated by using the PAUP* package
(36) as described previously (29). Potential positively selected sites
were identified using two phylogenetic methods. The ML ap-
proach implemented in the CODEML program (37) allows as-
sessment of the evidence for positive selection and estimation of
dN/dS ratios at individual codons, with values  1 suggestive of
selection. In a second approach, all amino acid changes were
mapped on an ML phylogenetic tree by using the parsimony al-
gorithm implemented in the MacClade program. As described
previously (29), sites had to fulfill one out of two criteria to be
deemed candidates for positive selection: (a) there were synapo-
morphic changes, occurring on the internal branches of the tree,
which indicates that they have been transmitted through the pop-
ulation, and (b) the site showed mutation of the same amino acid
on multiple terminal branches, which is likely to indicate a con-
vergent selective change that has arisen independently in multiple
lineages. For sequences derived from subjects with chronic infec-
tion, the numbers of sequences with and without a nonsynony-
mous substitution as aligned to the consensus of all sequences in
HLA-B8–positive and HLA-B8–negative subjects was determined
and compared using Fisher’s exact test.
Online Supplemental Material. ML phylogenetic are included
in Fig. S1. Using the parsimony algorithm implemented in
the MacClade program, tracking mutations that continue to fix-
ation in subject 99B and 02J are tracked. Online supplemental
material is available at http://www.jem.org/cgi/content/full/
jem.20041006/DC1.
Results
Evolution of T Cell Responses to HCV Proteins in Acute In-
fection. Three HCV positive subjects, 99B (needle stick in-
jury) and a transmission pair 02J (Fig. 1, donor) and 02K
(recipient), were screened for cellular responses using an
IFN-  ELISPOT assay (Table I). Screening of fresh and/or
Figure 1. Transmission pair: time course of infection. 02J donated
blood that was transfused into 02K 2 d later. Week 0 represents the day of
the transfusion event for the transmission pair. Subject 02J had not sero-
converted by the time of the blood donation. Both subjects seroconverted
subsequently between weeks 7 and 9, suggestive of infection of the donor
02J shortly before the blood donation.
Figure 2. Decline of B8-1395
T cell responses despite persistent
viremia. (A) 99B and the trans-
mission pair 02J (donor) and 02K
(recipient) presented with acute
infection and had persistent high
level viremia (HCV-RNA;  ).
During treatment (shaded area)
viral load declined to undetect-
able limits, but all three subjects
either relapsed after cessation of
therapy or had a viral break-
through. Longitudinal results for
the epitope B8-1395 ( ) as de-
termined by ELISPOT are shown
for 99B and 02J as spot-forming
cells per million (SFC/106 cells).
No CTL response was detected in
02K. (B) A tetramer for the HLA-
B8–restricted B8-1395 response
was used to follow the response
in 02J and 99B longitudinally
and is shown here as percentage
of all CD8  T cells. In 99B, the
response expanded after cessation
of therapy by week 62 (2.3%)
when viral load relapsed, but
subsequently declined despite persistent high level viremia. In 02J, the response expanded before treatment by week 10 (19.8%) and declined thereafter
despite persistent high level viremia before treatment was started. Staining was considered positive in 99B if tetramer-positive cells formed a cluster dis-
tinct from the tetramer-negative CD8  T cell population and the frequency of tetramer-positive cells was  0.1%. Backround staining was higher in 02J;
therefore only stainings  0.4% of the CD8  T cell population were considered positive in this subject.Timm et al. 1597
Table II. Viral Evolution within CD8 Epitope B8-1395
B8-1402a
H77 Week H L I F C HSKKKCDELAAKLVALG I NAVA
B8-1395
Bulk seq
datab 99B 5 . ... . .............S G .......
6 0 . ... . ...R....F....S G .......
191 . . . . . ..rr....f....S G .......
252 . . . . . ........ F....S G .......
02J 7 . ... . .........t.......V....
1 5 . ... . .......df........V....
3 0 . ... . .......d v........V....
5 7 . ... . ........ V .............
02K 7 . ... . ...R.....t.......V....
1 4 . ... . ...r.............V....
7 1 . ... . .................V....
Clonal
seq data 99B 5 9/14 . . . . . ......G......S G .......
2/14 . . . . . .............S G .......
1/14 . . . . . .............S G ..V....
1/14 . . . . . ........ P....S G .......
1/14 . . . . . ........... M .S G .......
60 11/12 . . . . . ...R....F....S G .......
1/12 . . . . . ...R....F.T. .SG.. . . . . .
191 9/13 . . . . . ........ F....S G .......
4/13 . . . . . .. R R .........S G .......
252 16/20 . . . . . ........ F....S G .......
1/20 . . . . . . P ...... F....S G .......
1/20 . . . . . ........ F....S G F..T...
1/20 . . . . . ........ F....S G ..T....
1/20 . . . . . ........ F V. . .SG.. . . . . .
02J 7 13/26 . . . . . .................V....
7/26 . . . . . ......... T.......V....
3/26 . . . . . .....R...........V....
1/26 . . . . . ...R.....T.......V....
1/26 . . . . . R ........ T.......V....
1/26 . . . . . ......................
15 4/8 . . . . . ........ F........V....
4/8 . . . . . ....... D .........V....
57 8/10 . . . . . ........ V .............
1/10 . . . . . ........ V ........T....
1/10 . . . . . ...R....V.......S.....
02K 7 06/9 . . . . . ...R.............V....
3/9 . . . . . ...R.....T.......V....
14 9/19 . . . . . ...R.............V....
7/19 . . . . . .................V....
3/19 . . . . . ...R.....T.......V....
71 13/14 . . . . . .................V....
1/14 . . . . . .. R..............V....
These sequence data are available from GenBank/EMBL/DDBJ under accession no. AY712793-712937.
aNote that a second overlapping HLA-B8–restricted CD8 epitope (B8-1402) was not targeted by 99B or 02J.
bLowercase letters in the bulk data indicate sites of mixed bases coding for different amino acids.CTL Escape in Acute HCV Infection 1598
frozen PBMCs at multiple time points between 3 and 80
wk after infection, including the earliest available time
point, revealed a dominant T cell response to the identical
peptide in both 99B and 02J (Fig. 2 A), as well as one addi-
tional T cell response in 99B (Table I). Subjects 99B and 02J
both mounted a CD8 T cell response targeting the previ-
ously described HLA-B8–restricted epitope B8-1395 (HS-
KKKCDEL; reference 38), which was confirmed using
HLA-matched B cell lines and ICS assays (not depicted), as
well as by tetramer analysis (Fig. 2 B). Ex vivo ELISPOT
screening at multiple time points before, during, and after
treatment detected no CD8 T cell responses in subject 02K.
MHC class I tetramers were used to follow the B8-1395
(HSKKKCDEL) CD8 T cell responses over the course of
infection in subjects 99B and 02J (Fig. 2 B). In subject 99B,
the B8-1395 response was not detectable by ELISPOT be-
fore treatment (Fig. 2 A), and due to limitations of cell
numbers, we were not able to perform a tetramer staining
from the first available time point. By week 21, while the
subject was undergoing therapy with viral loads at or below
detection limit in the quantitative assay, the response was
detectable at a low frequency (Fig. 2). During the relapse
after cessation of therapy when the viral load rebounded,
this response increased to a level of 2.3% of HCV-specific
CD8  T cells. However, upon follow-up 6 mo later, the
response against B8-1395 became undetectable despite per-
sistently high levels of viremia.
In subject 02J, the HLA-B8-1395–specific response rep-
resented the only CD8  T cell response detected. Although
this response was not detectable 7 wk after the blood trans-
fusion to 02K, in the following 4 wk during persistently
high viremia, this response peaked to levels of  19% CD8 
T cells (Fig. 2 B), and then rapidly declined despite high vi-
ral loads that eventually prompted initiation of anti-HCV
therapy. The HLA-B8-1395–specific response continued to
decline during treatment and did not reappear by week 40
or thereafter despite viral breakthrough (Fig. 2 B and not
depicted). The same course of the response was observed
using longitudinal ELISPOT assays (Fig. 2 A), indicating
that specific cells were continuously able to secrete IFN- .
Viral Sequencing Reveals Sequence Evolution Coincident with
Declining CD8 Responses. Next, we investigated whether
viral evolution and immune escape might be responsible
for the observed decline in these CD8 T cell responses. Se-
quence data from the HLA-B8-1395 epitope in subject
99B, aligned to the prototype H77 sequence, revealed evo-
lution in the targeted region (Table II). The sequence be-
fore treatment (week 5) largely corresponded to the H77
prototype sequence, with minor variations at the clonal
level. Two mutations developed at residues 4 and 9 of the
epitope (HSKRKCDEF) by week 60, the first available
viremic time point after discontinuation of treatment at
week 54. This region continued to evolve over time to-
ward a mixed population by week 191 (HSRRKCDEL
and HSKKKCDEF), with the latter variant becoming fixed
by week 252. No virus with the original dominant se-
quence was detectable by clonal analysis at week 60 or any
later time point (Table II).
In subject 02J, the dominant infecting sequence within
the HLA-B8 epitope was identical to that in subject 99B
(Table II). By week 15 after transmission, bulk sequence
data from the single targeted region illustrated the develop-
ment of mixed populations of aspartic acid and phenylala-
nine mutations in positions 8 and 9 of the epitope (HS-
KKKCDdf). Clonal data confirmed the presence of two
unique populations of virus with individual substitutions at
each position (HSKKKCDDL and HSKKKCDEF) occur-
ring with equal frequency and an absence of initial se-
quences (Table II). Development of these mutations, be-
fore treatment initiation, was coincident with the decline
of this CD8  T cell response (Fig. 2, A and B), and this re-
gion of NS3 continued to evolve toward a valine at posi-
tion 9 (HSKKKCDEV) ultimately becoming fixed. In the
COOH-terminal flanking region of the epitope, an addi-
tional change (alanine to threonine) was detectable early in
infection as a mixed population that subsequently became
undetectable by week 15.
Analysis of the dN/dS ratios yielded values  1 for posi-
tion 9 of the B8-1395 epitope in subject 99B and positions
4, 6, and 9 of the epitope in subject 02J, suggesting positive
selection at these sites (Fig. 3). In a second approach using a
parsimony algorithm, the observed mutations were mapped
on an ML phylogenetic tree (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20041006/DC1). This
analysis indicated selection within the epitope of the leu-
cine to phenylalanine mutation in position 9 in subject 99B
and the leucine to valine mutation in position 9 in subject
02J. Thus, for both of these HLA-B8 positive subjects
the dominant CD8 response was directed against the same
Figure 3. dN/dS values of acute subjects 99B and 02J. Analysis of dN/dS
values suggests selective pressure at position 9 in the targeted B8-1395
epitope (shaded area) in subject 99B and positions 4, 6, and 9 in subject
02J (ratio   1; dotted line). The residues are labeled with amino acids
represented in the H77 reference sequence. ML phylogenetic trees were
estimated by using the PAUP* package and dN/dS values were calculated
using the CODEML program.Timm et al. 1599
epitope, and in both persons epitopic mutations progressing
to fixation were selected.
Evidence for HLA-B8–associated CD8  T Cell–selective
Pressures in the B8-1395 Epitope at the Population Level.
Due to the observed viral evolution in epitope B8-1395 in
each of these two HLA-B8–positive subjects, we hypothe-
sized that escape from this CD8 response in chronic HCV
infection may be a common phenomenon. We obtained se-
quence data from additional randomly selected HLA-B8
positive (n   14) and HLA-B8–negative (n   16) individuals
with chronic HCV infection. 8 out of 14 (57%) HLA-B8–
positive individuals exhibited sequence variation within the
B8-1395 epitope relative to the H77 genotype 1a reference
sequence (Table III). In contrast, none of the 16 HLA-B8–
negative subjects (0%) showed any sequence variation, sug-
gestive of HLA-B8–mediated selective pressure against this
region of NS3 (P   0.001). The most frequent variant (4/14)
was an arginine in position 4 (HSKRKCDEL). In addi-
tion, there was a modest increase in polymorphisms in the
COOH-terminal region of the dominant HLA-B8 epitope,
which is the location of a second partially overlapping HLA-
B8–restricted epitope (B8-1402; ELAAKLVAL). Together,
these data suggest that sequence polymorphisms within this
region of NS3 in persons with chronic HCV infection are
associated with HLA-B8–restricted immune pressure.
Impact of Variant Peptides on MHC Class I Binding and T
Cell Recognition. The in vivo decline of these B8-1395–
specific responses, coincident with sequence evolution, sug-
Table III. HLA-B8–associated Selective Pressures in B8-1395 at the Population Level
B8-1402
Genotype I K G G R H L I F C HSKKKCDELAAKLVALGINA VAYYR G
B8-1395
HLA-B8
positive
1 a . ...... . ..... R ...... T ...... . .. ......
1 a . ...... . .........D... R ........ ......
1 a . ...... . ..... R ................ ......
1 a . ...... . ................... V .. ......
1 a . ...... . .........D..S R ..... V .. ......
1 a . ...... . ...................... ......
1 a . ...... . .... R ................. ......
1 a . ...... . ..........F........... ......
1 a . ...... . ............. R ..... V .. ..F...
1 a . ...... . ................... V .. ......
1 a . ...... . ...................... ......
1 a . ...... . ..... R ................ ......
1 a . ...... . ...................... ......
1ba . ...... . ..... R .........SS.. L .. ......
HLA-B8
negative
1 a . ...... . ................... V .. ......
1 a . ...... . ...................... ......
1 a . ...... . ................... V .. ......
1 a . ...... . ...................... ......
1 a . ...... . ................... V .. ......
1 a . ...... . ................... V .. ......
1 a . ...... . ...................... ......
1 a . ...... . ...................... ......
1 a . ...... . ................S.. V .. ......
1 a . ...... . ...................... ......
1 b . ...... . ...............S G .. L .. ......
1 b . ...... . ...............SS.. L .. ......
1 b . ...... . ...............S G .. L .. ......
1 b . ...... . ...............S G .. L .. ......
1 b . ...... . ...............S G .. L .. ......
1 b . ...... . ...............S G .. L .. ......
These sequence data are available from GenBank/EMBL/DDBJ under accession no. AY707283-312.
aNote that some differences in the COOH-terminal flanking region of the epitope are specific for genotype 1b.CTL Escape in Acute HCV Infection 1600
gested a significant impact of the mutation on T cell recog-
nition. To test this, peptides representing putative escape
variants were synthesized and tested in ELISPOT and 51Cr-
release assays using serial dilutions of peptide and B8-1395–
specific CD8  T cell lines. The most frequently observed
variant in chronically HCV-infected B8-positive subjects
(HSKRKCDEL) was less efficient than the parental se-
quence in stimulating IFN-  secretion and cytotoxicity
consistent with a CD8 escape mutation (Fig. 4, A and B).
Using the first emerging variant in subject 99B by week 60
(HSKRKCDEF), IFN-  secretion was similarly reduced.
However, unexpectedly, peptides representing the fixed
variants from subjects 02J and 99B (HSKKKCDEV and
HSKKKCDEF, respectively) were recognized as well as the
initial sequence (Fig. 4, A and B). Binding assays revealed a
reduction of the affinity of one variant (HSKKKCDEV) for
the HLA-B8 molecule compared with the prototype se-
quence (64% reduction of binding), whereas the other ob-
served mutations did not alter MHC binding (unpublished
data). These results suggest that the variant peptides could
bind sufficiently to HLA-B8 when presented exogenously
and that neither MHC binding nor T cell receptor recogni-
tion was substantially compromised by the mutations.
Evidence for Impaired Recognition of Endogenously Processed
Antigen. To address more physiologically whether the
mutations arising in subjects 02J and 99B might be affecting
antigen processing, the wild-type and variant B8-1395 se-
quences were expressed endogenously to allow for normal
processing and presentation of the epitopes within the cy-
tosol and ER of the cell. To accomplish this, mRNA con-
taining the epitope region derived from autologous virus of
subject 02J at weeks 7, 15, and 57 was designed. Different
clones with the prototype sequence (HSKKKCDEL) with
variant sequences (HSKKKCDEF and HSKKKCDEV) and
one additional clone harboring an A-T change in the
COOH-terminal flanking region (HSKKKCDELT) served
as a template. The precise composition of these PCR prod-
ucts was confirmed by sequencing. The template also in-
cluded on the 3  end a nucleotide sequence coding for
the known HLA-B8–restricted HIV nef epitope FL8
(FLKEKGGL) as a positive control. mRNA was transfected
into HLA-B8 positive B cells that served as target cells in
an ICS assay. B cells transfected with the prototype se-
quence mRNA (HSKKKCDEL) were able to stimulate
substantially more IFN-  secretion from the B8-1395–spe-
cific T cell line (16.0%) compared with the variant mRNA
constructs HSKKKCDEF and HSKKKCDEV (1.8 and
1.9%, respectively), suggesting that the variant sequence
was interfering with the ability of the B8-1395 epitope to
reach the cell surface and be presented to the T cell (Fig.
5). The observed A-T change in the COOH-terminal
flanking region in 02J in week 7 (HSKKKCDELT) did not
Figure 4. Impact of variant peptides on IFN-  secre-
tion  and cytotoxicity. Variant peptides derived from
the sequence data were synthesized and tested in log10
dilutions in an IFN-  ELISPOT (A) and 51Cr release
cytotoxicity assay (B). Data are shown as spot-forming
cells (SFC) per million and specific lysis in percentages.
The most frequently detected variant in the chronic
subjects (HSKRKCDEL;   ) and the first emerging
variant in 99B (HSKRKCDEF;  ) was less efficient in
stimulating IFN-  secretion compared with the wild-
type sequence (HSKKKCDEL;  ). Unexpectedly,
fixed variants from later time points of 99B and 02J
(HSKKKCDEF;   and HSKKKCDEV;  ) did not have
any substantial impact on IFN-  secretion or cytotoxicity.
Figure 5. Variant sequence
derived from 02J compromises
processing and presentation of
the B8-1395 epitope. B cells
were transfected with mRNA
derived from subject 02J repre-
senting the acute prototype se-
quence (HSKKKCDEL), variant
sequences (HSKKKCDEF and
HSKKKCDEV) and one addi-
tional construct with a mutation in
the COOH-terminal flanking
region (HSKKKCDELT). The
transfected constructs included the
HIV nef FL8-epitope on the 3 
end. In the positive control, the
FL8 clone recognized B cells us-
ing all four constructs for transfection. B cells transfected with the prototype sequence (HSKKKCDEL) stimulated substantially more IFN-  when coin-
cubated with a B8-1395–specific cell line compared with B cells transfected with the variant sequences (HSKKKCDEF and HSKKKCDEV). Numbers
in each top right quadrant represent the percentage of IFN- –positive CD8 cells.Timm et al. 1601
alter IFN-  secretion (17.9%). As a control, B cells trans-
fected with all mRNA constructs stimulated IFN-  secre-
tion when coincubated with the FL8-specific clone, indi-
cating that all constructs were expressed though expression
of the two variant constructs was slightly less efficient. After
normalizing for transfection efficiency, IFN-  secretion
was reduced between five- and eightfold using the variant
sequence in three repeated experiments. These data suggest
that the COOH-terminal mutation was altering the normal
antigen processing of this epitope by preventing its efficient
presentation at the surface of an infected cell.
Reversion of a Transmitted CD8 Escape Mutation. Clini-
cal data indicated that subject 02K was infected through a
blood transfusion from subject 02J, which was confirmed
by early sequence data from both subjects derived 7 wk af-
ter transmission (unpublished data). This provided a unique
opportunity to examine whether HCV epitopes differen-
tially evolve in the setting of two different host genetic
backgrounds. Surprisingly, comparison of the full-length
sequences of these two viruses by bulk sequencing at this
first available time point revealed only three nucleotide dif-
ferences, two of which resulted in altered amino acids lo-
cated in NS3 at position 1398 and in NS5 at position 2413
(unpublished data). Therefore, one of the nonsynonymous
substitutions in 02K resided within the B8-1395 epitope
observed previously to escape in subject 02J (Table II) and
represented one of the potential sites under selective pres-
sure in the donor 02J (Fig. 3). These data suggested that a
viral escape mutant from this B8 epitope in 02J was trans-
mitted to 02K and represented the establishing infecting
strain in 02K. In fact, clonal sequence data from donor 02J
at the first available time point, 7 wk after the transfusion
event, revealed a minor proportion (1/26) of this variant
(Table II). Follow-up analysis in 02K revealed that, over
time, this transmitted arginine mutation was replaced by
the lysine residue that represents the consensus sequence of
the HCV 1a strain. These data suggest that the virus infect-
ing 02K harbored the HLA-B8-1395 escape mutation HS-
KRKCDEL, and that continuous replication of this virus in
the absence of HLA-B8–restricted CTLs enabled reversion
of this mutation back to wild-type sequence.
Discussion
The means by which HCV is able to establish a persistent
infection in the face of an activated host immune response
are still unclear. It is believed that strong and broadly di-
rected CD4  and CD8  T cell responses play a role in con-
tainment of the virus in the acute phase of infection (2–6).
Therefore, one possible mechanism of immune evasion is
the emergence of escape variants that impair recognition by
established CTL responses as described for other viral infec-
tions (22–25). Here, we demonstrate escape from a domi-
nantly targeted CTL epitope in two subjects with acute
HCV infection, resulting in the rapid ex vivo loss of these
responses. These data indicate that the cellular immune re-
sponse is capable of exerting strong selective pressure on the
virus during the acute phase of HCV infection.
A strong association between persistence of HCV vire-
mia after acute infection and the emergence of escape vari-
ants has been shown in the chimpanzee model (27). How-
ever, direct evidence of viral escape and selective pressure
of CTL in humans with HCV infection has been more dif-
ficult to illustrate. The current paper provides convincing
evidence of immune selection pressure in both the acute
and chronic phases of infection for an epitope that is a
dominant target of the initial immune response. Although
the mutations did not appear to impact MHC class I bind-
ing or TCR recognition, intracellular expression of the
variant epitope was able to illustrate an impact of these mu-
tations upon antigen processing and presentation.
Recent studies in HIV-1 directly illustrate that mutations
that alter antigen processing can be selected in vivo (39, 40),
and one paper demonstrated that these mutations can also
reside within the epitope (41), suggesting that the frequency
of escape mutations might be underestimated using syn-
thetic peptides. A recent paper also now demonstrates for an
HCV epitope altered processing by a mutation in the
COOH-terminal flanking region of a frequently targeted
HLA-A2–restricted epitope (42). In the present case, pre-
sentation of endogenously processed antigen revealed the
important impact of an immunologically selected mutation.
The power of assays using endogenously synthesized anti-
gen is clear, but previous studies have been limited largely
because they relied on the cumbersome generation of re-
combinant vaccinia virus constructs for infection of B cells.
Here, we apply a novel method based on transfection of tar-
get cells with synthetic mRNA encoding a portion of HCV
NS3 derived from clinical isolates before and after antigenic
escape. Our method is based on a technique originally de-
veloped for delivery of tumor antigens to dendritic cells
(43). With this simple and rapid technique, we were able to
demonstrate that the observed sequence variation in the B8-
1395 epitope compromised its presentation and recognition.
In addition to the acute immune escape observed within
the B8-1395 epitope, chronically infected patients express-
ing the HLA-B8 allele also demonstrated sequence poly-
morphisms within B8-1395. This was in stark contrast with
all other HLA-B8 negative subjects who expressed the pro-
totype H77 sequence. This analysis demonstrates that selec-
tive pressure leading to escape in this region was associated
with the HLA-B8 allele. More importantly, these data sug-
gest that mounting of this response in HLA-B8 positive
subjects must also be relatively common. In our cohort, no
corresponding B8-1395–specific CTL response was detect-
able in the studied HLA-B8 positive subjects with chronic
infection, even after a single round of peptide-specific stim-
ulation (unpublished data). Assuming there was a CTL re-
sponse that has selected for the escape mutation, the fate of
this T cell population is unclear. It has recently been shown
in SIV-infected macaques that an escape mutation in a
CD8 epitope that rapidly reverts in the absence of the re-
stricting HLA allele is maintained in the presence of a
barely detectable CD8 response (44). These data and the
fact that the mutations were stable in chronic HCV-
infected subjects suggest that selective pressures are stillCTL Escape in Acute HCV Infection 1602
present in the chronic phase and simply not detectable with
our assays in PBMCs.
Recent studies in HIV-1 and SIV suggest that CD8 es-
cape mutations can be unstable and may revert upon trans-
mission to a new host in which the original selecting force
is absent (39, 44, 45). The data presented here suggest that
a similar phenomenon can occur in HCV infection. In all
three subjects with acute infection, the K-R mutation in
position 4 of the B8-1395 epitope was unstable and even-
tually replaced by the consensus residue for this position.
However, in both HLA-B8–positive subjects, a second es-
cape mutation became predominant in position 9 (L-V or
L-F, respectively) that continued to fixation. These data
suggest that the mutation in position 9 that affects presenta-
tion of the endogenously processed epitope has a selective
advantage over the K-R mutation in position 4. One may
speculate that the observed compromised T cell recogni-
tion by the K-R mutation in position 4 provides a short-
term benefit, but is only transiently selected until the more
advantagous processing mutation in position 9 develops.
However, as the K-R mutation is the most frequently ob-
served polymorphism in subjects with chronic HCV infec-
tion, it therefore seems unlikely that it is generally unstable
in all subjects. Transient escape mutations, arising before
fixation of another mutation, have also been described in
the HCV-infected chimpanzee model as well as for other
viral infections, such as HIV (27, 39, 46).
Similarly, the data from subjects with chronic HCV in-
fection illustrate strong purifying selection pressure on this
region of NS3. HLA-B8 represents a relatively frequent al-
lele in the Northern American population with a genotype
frequency of 10% in Caucasians and 5% in African Ameri-
cans (47). Thus, in the absence of reversion, variants would
expected to be present at least in some HLA-B8–negative
subjects with chronic infection. The complete lack of se-
quence polymorphisms in all HLA-B8–negative subjects
supports reversion of mutations in the B8-1395 epitope in
the absence of T cell–mediated selection pressures. The
implications of the observed reversion are twofold. First,
they suggest that despite viral escape and transmission of
these mutations, some mutations may not continue to ac-
cumulate on a population level, which might otherwise
result in deletion of that epitope over the course of the
epidemic. Second, they suggest that some CD8 escape mu-
tations may exact a fitness cost to the virus, much like
HIV-1–associated drug resistance mutations (48) that re-
quire the virus to revert where possible to the more fit
wild-type sequence (49).
It was surprising that a variant clone present only at low
frequency in the donor 02J predominated in the recipient
02K early in infection. Although ELISPOT and tetramer
analysis of the first time point of subject 02J did not detect
CTL responses in PBMCs, selective pressure may have al-
ready been underway but below the detection limit in the
peripheral blood. The dominance of this low frequency
clone from the donor in the early phase after transmission
might be caused by an advantage of the variant clone during
primary infection as has been described previously during
vertical transmission (50) However, a recent paper investi-
gating quasispecies complexity after transmission through a
blood transfusion did not observe this phenomenon (51). A
second possible explanation is that the frequency of the
transmitted variant was higher 7 wk earlier at the time the
transfusion took place. Unfortunately, no sample of the in-
oculum was available to further address this question.
Although the present data indicate reproducible selective
pressure on HCV mediated through the HLA-B8 allele,
and clearly show that CD8 selection pressure influences vi-
ral evolution, the overall impact of immune escape on fail-
ure to contain HCV in humans is unclear. The limited
magnitude and breadth of HCV-specific CTL responses as
compared with other viruses such as HIV is striking (33);
thus, other mechanisms such as failure to prime a response
or secondary failure due to exhaustion or impaired effector
function may play a role. The effector and maturation phe-
notype of the B8-1395–specific cells (CD27 /CD28 ; un-
published data) was not substantially different from previ-
ously published studies, where chronically infected subjects
as well as subjects that continued to resolve infection were
analyzed (4, 52). As described for HIV, clearly not all
epitopes escape during the course of infection, some are
conserved despite consistently detectable CTL responses
over time (26). This likely reflects the balance between the
strength of the immune response and the ability of the viral
protein to accommodate sequence polymorphisms, and
each of these forces is undoubtedly shaping the global se-
quence diversity of HCV.
In conclusion, these data provide support that virus-spe-
cific CD8  T cell responses drive viral evolution during
the acute phase of HCV infection in humans and illustrate
that viral escape in acute HCV infection is one mechanism
that may be contributing to viral persistence. Moreover,
the results display the power of analyzing the presentation
of endogenously synthesized antigen, which revealed a
functional impact of the emerging mutants. The reproduc-
ible evolution within a targeted CD8 epitope on the popu-
lation level suggests that more detailed studies are needed
to broadly examine viral evolution in hepatitis C and its
impact on CTL recognition.
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